Aim To briefly review and discuss the literature on why patients still require surgery for the late complications of proliferative diabetic retinopathy (PDR). Methods: Literature review. Results The reasons for incomplete coverage of screening and screening failures can be divided into non-modifiable and potentially modifiable risk factors. The non-modifiable group includes duration of diabetes, age, genetic predisposition, ethnic differences, and the various reasons for vitrectomy when optimum laser treatment has been applied at the appropriate stage of the disease process. The potentially modifiable group includes glycaemic control, blood pressure control, lipid control, and cessation of smoking in type 1 diabetes. Other potentially modifiable factors include adequacy of screening, including reaching the regular non-attender, and attempting to modify the psychological factors that lead to late presentations including depression and eating disorders. Other potentially modifiable risk factors are optimising laser treatments and the potential use of anti-VEGF therapy to prevent vitrectomy in iris neovascularisation and neovascular glaucoma. Conclusion Surgery for the late complications of PDR continues to be required even in some patients who have received optimal medical care and optimal laser treatment. There are certain modifiable risk factors that could be altered and further research is needed in specific fields, particularly with regard to the adequacy of laser treatments, the use of anti-VEGF agents in iris neovascularisation, and in the role of psychological support in reducing the type of late complications leading to surgery for PDR.
Introduction
It was apparent at the Liverpool Conference 1 on 'Screening for Diabetic Retinopathy in Europe' in 2005 that some countries (eg, Uzbekistan) had no available lasers at that time for their population. However, I have made the assumption in this article that the patient group that we are discussing has access to both laser treatment and surgery for the late complications of proliferative diabetic retinopathy (PDR).
In this review, my aim was to identify modifiable and non-modifiable risk factors relating to late complications of diabetic retinopathy and to discuss potential ways in which one might reduce the modifiable risk factors.
I have defined surgery for late complications of diabetic retinopathy as 1. vitrectomy for those complications of diabetic retinopathy that are widely accepted as requiring this form of treatment; 2. surgical treatment for rubeosis iridis with or without secondary glaucoma, due to diabetic retinopathy.
I have excluded scatter or panretinal laser treatment from the definition of surgery for late complications of diabetic retinopathy, as this is the recognised treatment for high-risk proliferative diabetic retinopathy.
Methods
The methodology of the literature review was as follows: 2. AgeFthere is a rather complex link with age in the Wisconsin Epidemiological Study [10] [11] [12] showing that in those whose age of diagnosis was less than 30 years and who had diabetes of 10 years duration or less, the severity of retinopathy was related to older age at examination, whereas when the age at diagnosis was 30 or more years, the severity of retinopathy was related to younger age at diagnosis. In the UKPDS, 13 in those who already had retinopathy, progression was associated with older age. 3. Genetic predisposition 14 Fin a study on 4800 adults with type I diabetes in Finland, a familial clustering of proliferative retinopathy was found in patients with type I diabetes, which could not be accounted for by conventional risk factors, suggesting a genetic component in the pathogenesis of proliferative retinopathy in type I diabetes 4. Ethnic differencesFtwo studies, 15, 16 one comparing Hispanics, African Americans, and non-Hispanic whites and the other comparing European, Maori, and Pacific people, suggested that ethnic differences could not be explained by an imbalance in traditional risk factors such as age, duration of diagnosed diabetes, HbA1c, and blood pressure. 5. The requirement for vitrectomy despite optimum laser treatment being applied at the appropriate stage of disease progression.
Of the eyes that were treated at the stage of high-risk proliferative diabetic retinopathy under the Early Treatment Diabetic Retinopathy Study research conditions, 4% required vitrectomy 17 within 5 years and 2.1% of eyes treated with early full scatter photocoagulation still needed vitrectomy. Although this study is 15 years old, it showed that optimum laser does not always prevent a vitrectomy operation. It may be that there are other modifiable factors that could have reduced the risk of vitrectomy in this small percentage of patients but optimum laser treatment alone did not. The following are reasons why vitrectomy may be required despite optimum laser treatment:
(a) Non-clearing vitreous haemorrhageFfollowing the results of the diabetic vitrectomy study, 18, 19 vitrectomy is usually considered early 2. Blood pressure controlFcontrol of systemic hypertension has been shown to reduce the risk of new onset DR and slow the progression of existing DR.
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The following are also potentially modifiable risk factors:
3. Lipid controlFthere is evidence 28, 29 that elevated serum lipids are associated with macular exudates and moderate visual loss and partial regression of hard exudates may be possible by reducing elevated lipid levels. 4. Smoking is considered to be a risk factor for type 1 disease, 30 although the evidence for smoking being a risk factor in type 2 disease is controversial with the UKPDS data, 13 suggesting that smoking may have a protective effect on retinopathy, even though it is a major risk factor for mortality. 5. Incomplete coverage of screening.
Posters at the Liverpool Conference 1 in 2005 showed that there were large variations in screening activity in Europe, with annual national diabetic retinopathy screening programmes in England, Scotland, Wales, Northern Ireland, and Iceland, whereas in Denmark, regional programmes have developed and, in many other European countries, for example Eire, France, Germany, Greece, Israel, Italy, Luxembourg, Netherlands, Portugal, and Spain, local screening programmes have developed upon the initiative of individual persons, and coverage across the country is variable. In Eastern Europe, the provision of screening was very variable. In the United States, provision of screening is mostly for those who can pay, and it is estimated 31 that there are more than 47 million Americans who have no health-care insurance.
Even in countries in which comprehensive screening programmes exist and there are no economic considerations for attendance for a person with diabetes, there are variations in uptake. Zoega 32 showed a significant relationship between screening compliance and visual outcome in patients with diabetes in the Icelandic screening programme. Diabetic patients (type I and type II) listed in the National Register for the blind had significantly lower rates of screening compliance (27 þ 38% than those in the control group (77 þ 26%). In the treatment phase, once diabetic macular oedema or proliferative diabetic retinopathy was diagnosed, there was no significant difference (83 þ 27 versus 87 þ 12%). Gray 33 has shown a link between the number of reminders required for attendance in the screening programme in Somerset, United Kingdom and the grade of retinopathy identified. In a study 34 in Gloucestershire, United Kingdom, sight-threatening diabetic retinopathy was found to be present most frequently in the most deprived socio-economic group, and this group was the least likely to attend screening.
Psychological aspects causing late presentation
As vitrectomy operations are performed for more advanced stage disease, it follows that patients who present late with advanced disease are more likely to require a vitrectomy. Gale 35 wrote in his review article on 'How to survive diabetes' that the likely major determinants of long-term survival are 'metabolic control, destiny and character'. He also wrote that it was 'sad to relate, we have made little progress in understanding the human determinants of long-term survival with diabetes, and the social, behavioural and psychological basis of long-term diabetes has not been studied, despite the central role of self-management in achieving this outcome'. Szydlo 36 found that the diagnosis of DM is a significant stress factor not only for patients but also for their environment. Children with DM are sometimes stigmatised by their peers and relatives who do not understand the illness or are frightened by it. The family's response to the diagnosis of DM may have a negative effect on glycaemic control. Rose 37 studied the multitude of somatic and psychological factors in achieving treatment goals and found that belief in self-efficacy and active coping behaviour influenced maintaining blood glucose levels close to normal. Weinger 38 recommended that interventions designed to help patients overcome attitudinal barriers should be incorporated into medical programmes geared towards improving glycaemia. Gale 35 suggested that anyone who came into contact with long-term survivors of diabetes will probably agree that these are self-directed people with a lot more than diabetes to live for.
Patients with diabetes have an increased risk of depressive symptoms, which may have an additional negative effect on their quality of life. A recent systematic review by Schram 39 summarised the current knowledge on the association between depressive symptoms and quality of life in individuals with diabetes. The review concluded that in addition to the considerable effect of depression on quality of life in individuals with diabetes, depression also contributes to poor self-care, poor adherence to medical treatment, higher rates of medical morbidity and mortality, and increased health-care costs.
One area that I have been aware that causes significant problems in my own patients with respect to late presentations and the need for surgery for the late complications of PDR is eating disorders in both type I and type II 40 diabetes. This has been studied by GoebelFabri 41, 42 in patients with type I diabetes and can cause particular problems with metabolic control and progression to very severe diabetic retinopathy in young women. Insulin omission and reduction and eating disorder symptoms unique to diabetes mellitus are strongly associated with an increased risk of severe microvascular complications of diabetes mellitus such as advanced proliferative DR requiring vitrectomy.
Adequacy of laser treatment
There is an optimum amount of laser treatment for each individual patient. The Diabetic Retinopathy Study (DRS) recommended that the amount of retina treated is equivalent to an area of 157-314 mm 2 , whereas the ETDRS recommended an area equivalent from 236 mm 2 to 314 mm 2 . Reddy 43 showed that the amount of initial treatment required for regression may be considerably more than that recommended by the Diabetic Retinopathy Study and that more extensive treatment was required with more retinopathy risk factors.
In 1998, Bailey 44, 45 reported the results of the UK National Diabetic Retinopathy Laser Treatment Audit, which showed that many UK Ophthalmologists were undertreating compared with the DRS or ETDRS protocols. For the subgroup with the equivalent of highrisk characteristics who were given their initial treatment in one session (n ¼ 65), the median retinal area treated was 104. Iris neovascularisation and glaucoma secondary to diabetic retinopathy are believed to be caused by the vasoproliferative growth factors produced by an ischaemic retina. 46 The aim of treatment is therefore to treat the ischaemic retina with panretinal photocoagulation but applying panretinal photocoagulation can be made more difficult because of corneal oedema produced as a consequence of raised intraocular pressure. Some patients require a vitrectomy, 47 but the visual prognosis depends on how early the iris neovascularisation and elevated intraocular pressure are detected and treated. Others require transscleral diode laser cyclophotocoagulation, 48 but there is a risk of hypotony and phthisis in diabetic neovascular glaucoma in eyes that have had multiple pars plana vitrectomies. There are some recent reports 49, 50 of shortterm regression of iris neovascularisation after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Jiang 50 conducted a retrospective analysis of 28 eyes of 22 patients. Significant regression of iris neovascularisation was noted in 20 eyes (71.4%). Further studies are needed to evaluate long-term results but this may offer some patients a time period during which panretinal photocoagulation can be applied without needing to resort to vitrectomy or transscleral diode laser cyclophotocoagulation.
Discussion
This review has shown that there are numerous nonmodifiable and modifiable risk factors for surgery for the late complications of PDR. In different health-care environments, the question arises as to whether we could be doing anything more about the modifiable risk factors.
There is rightly a considerable emphasis among physicians and primary care practitioners on control of glycaemia, blood pressure, and lipids. Screening programmes vary in different countries but efforts need to be made to screen the regular non-attenders, as these are the patients most at risk. I believe that more studies should be carried out following the results of the Royal College of Ophthalmology audit to improve training in laser treatment in the United Kingdom and to re-audit the results that were presented in 1999; there is no current evidence that laser treatments have improved since that time. Further work is required to understand the current levels of laser coverage for patients being referred for vitrectomy and what one might consider to be the optimum level of laser treatment, given that the vitrectomy complication rates continue to reduce.
The early results of the use of anti-VEGF agents in iris neovascularisation are encouraging but further research is needed in this field to inform the optimum timing and dose of this treatment.
Further work also needs to be carried out into the social, behavioural, and psychological basis of long-term diabetes and into the role of psychological support in reducing the type of complications leading to surgery for PDR.
